Abstract Objective： This randomized controlled clinical study was to assess and compare the efficacy and safety of two chemoradiotherapy regimens [cisplatin ＋ 5-fluorouracil ＋ 3 dimensional conformal radiation ther...Abstract Objective： This randomized controlled clinical study was to assess and compare the efficacy and safety of two chemoradiotherapy regimens [cisplatin ＋ 5-fluorouracil ＋ 3 dimensional conformal radiation therapy （3DCRT） and cisplatin ＋ weekly docetaxel ＋ 3DCRT] in patients with locally advanced esophageal squamous cell carcinoma. Methods： A total of seventy-four patients with clinical stages liB to IIIB esophageal squamous cell carcinoma were enrolled. Chemotherapy for PF group comprised 5-fluorouracil at days 1-5 （250 mg/m2/d） and cisplatin （20 mg/m2） at days 1-3 of every 28-day cycle; full treatment course included 2 cycles. Chemotherapy for DP group comprised docetaxel （20 mg/m2） and cisplatin （20 mg/m2） at days 1,8, 15, 22, 29, and 36. Both groups treated with concurrent 60 Gy 3DCRT at 200 cGy/d. Results： Seventy-four patients were enrolled and 71 completed the planned treatment, with a follow-up rate of 95.94%. Short-term curative effect was not statistically significant between the two groups （P = 0.471）. The 2-year survival rates were 65.7% and 61.1%, respectively （P = 0.806）, 5 years survival rates were 34.29% and 27.78%, respectively （P = 0.221）, and there was no significant difference by Fisher test （P = 0.734）. As common side effects, incidence rates of radioactive esophagitis and hematological toxicity were lower in DP group. Conclusion： For locally advanced esophageal cancer patients, current chemoradiotherapy with chemo- therapy regimen of weekly docetaxel plus cisplatin has equal curative effect with 5-fluorouracil plus cisplatin, but well-tolerated by reducing side effects such as radioactive esophagitis and bone marrow suppression.展开更多
We report the successful treatment of multiple lung metastases after hepatic resection for hepatocellular carcinoma (HCC) with combined docetaxel, cisplatin (CDDP), and enteric-coated tegafur/uracil (UFT-E). A 68-year...We report the successful treatment of multiple lung metastases after hepatic resection for hepatocellular carcinoma (HCC) with combined docetaxel, cisplatin (CDDP), and enteric-coated tegafur/uracil (UFT-E). A 68-year-old man was diagnosed with multiple lung metastases of HCC 7 mo after partial hepatectomy for HCC. Oral UFT-E was given daily and docetaxel and CDDP were given intra-arterially (administered just before the bronchial arteries) every 2 wk via a subcutaneous injection port. One month after starting chemotherapy, levels of tumor marker, protein induced by vitamin K absence(PIVKA--), decreased rapidly,and after a further month, chest X-ray and computed tomography revealed the complete disappearance of multiple liver metastases. Two years after the combined chemotherapy, HCC recurred in the liver and was treated but no pulmonary recurrence occurred. In the absence of a standardized highly effective therapy, this combined chemotherapy with docetaxel, CDDP and UFT-E may be an attractive option for multiple lung metastases of HCC.展开更多
Objective: The aim of this study was to evaluate the efficacy and toxicity of modified docetaxel, cisplatin and calcium folinate (CF)/5-fluorouracil (mDCF) combination therapy for 27 patients with recurrent or metasta...Objective: The aim of this study was to evaluate the efficacy and toxicity of modified docetaxel, cisplatin and calcium folinate (CF)/5-fluorouracil (mDCF) combination therapy for 27 patients with recurrent or metastatic gastric adeno- carcinoma (R/MGC). Methods: From May 2006 to July 2007, 27 R/MGC patients (18 were male and 9 were female) with a median age of 49 years (range19-66) were consecutively enrolled. The mDCF protocol included 50 mg/m2 docetaxel for 1 day and 25 mg/m2 cisplatin on d2-3, 200 mg/m2 CF on d2-3 and 2000 mg/m2 5-fluorouracil (5-FU) CIV (continous infusion) for 46 h on d2-3, repeated every 2 weeks. Results: Twenty-seven patients were evaluable for efficacy and toxicity. A median of 4.5 cycles was given. One complete and 12 partial responses were observed for an overall intent to treat response rate (RR) 48.1% [95% CI (confidence intervals): 32%-64%]. Median time-to-progression (TTP) was 6.2 months and overall survival (OS) was 11.8 months. Twenty-seven (100%) patients experienced bone marrow suppression, and of them 48.9% were Grade 3-4 (16.3% were Grade 4). Two patients (7.4%) ceased chemotherapy because of bone marrow suppression. WHO Grade 1-4 non-hematological toxicity, such as oral mucositis, nausea/emesia, peripheral neuropathy, liver dysfunction, diarrhea, nephrotoxicity and cardiotoxicity, occurred in 59.2%、51.9%, 48.1%, 44.4%, 25.9%, 18.5% and 11.1% patients, respectively, and most of them were Grade 1-2. No patient died due to chemotherapy toxicity. Conclusion: mDCF regimen is effective in treating R/MGC with a high RR and long TTP/OS in this trial. Despite its severe hematotoxicity, this regimen has some advantages such as no cross-resistance with paclitaxel (paclitaxel-resistant patients RR 2/6). These results suggested that the mDCF regimen worth further investigation in clinical study of R/MGC treatment.展开更多
Objective： The aim of this study was to evaluate the clinical efficacy and side effects of docetaxel/cisplatin regiment and gemcitabine/cisplatin regiment in the patients with advanced non-small-cell lung cancer （NS...Objective： The aim of this study was to evaluate the clinical efficacy and side effects of docetaxel/cisplatin regiment and gemcitabine/cisplatin regiment in the patients with advanced non-small-cell lung cancer （NSCLC）. Methods： Seventy-six patients with advanced NSCLC who were chemotherapy-naive were enrolled in two groups. In docetaxel group （DP group） the patients received docataxel 75 mg/m^2 and cisplatin 60 mg/m^2 on day 1. In gemcitabine group （GP group） the patients received gemcitabine 1000 mg/m^2 on day 1 and day 8. The dosage of cisplatin was the same as DP group. The two regiments were administrated intravenously every 21 days as a cycle, each patient received 2-4 cycles. All patients were followed up until disease progressed or patients died. Results： The overall response rates were 43.5% in DP group and 45.9% in GP group. The response rate was significantly different between the initial treated group and retreated group in both two groups （53.8% vs 23.0% in DP group and 56% vs 25% in GP group, P 〈 0.05, respectively）. The main side effects were bone marrow suppression and thrombocytopenia. Conclusion： Docetaxel/cisplatin regiment and gemcitabine/cisplatin regiment for the patients with advanced NSCLC were efficient and well-tolerated chemotherapeutic approachs with low toxicity levels. The efficacy and major toxicity in two groups were similar.展开更多
Objective： The aim of this study was to investigate the efficacy of weekly docetaxel （TXT）, cisplatin （DDP） combined with continuous infusion of low dose fluorouracil （FU） on advanced gastric carcinoma. Methods...Objective： The aim of this study was to investigate the efficacy of weekly docetaxel （TXT）, cisplatin （DDP） combined with continuous infusion of low dose fluorouracil （FU） on advanced gastric carcinoma. Methods： Forty patients with advanced gastric carcinoma were randomly divided into two groups： the research group and the control group with 20 cases in each group. Patients in the research group were given TXT 40 mg/m^2 on dl and d8 plus DDP 30 mg/m^2 on days 1, 3. FU 200 mg/m^2 was infused continually from day 1-14. Patients in control group received ELF regimen therapy. Etoposide （VP- 16） 120 mg/m^2, calcium folinate （CF） 200 mg/m^2, and FU 500 mg/m^2 were given on days 1 and 3. Twenty-eight days were regarded as one cycle. At least two cycles must be completed. The short-term efficacy, adverse reaction, quality of life （QOL）, and overall survival （OS） were recorded. Results： The clinical efficacy could be evaluated in 19 patients of research group and 17 patients in control group. The efficacy of research group was significantly better than that in control group （52.63% vs 17.65%, χ^2 = 4.760, P = 0.041）. However, the difference was not significant in the frequency of adverse reaction, QOL, median survival time, and OS between the two groups （P 〉 0.05）. Conclusion： The short-term efficacy of weekly docetaxel and cisplatin plus low dose FU was better than traditional ELF regimen in the treatment of advanced gastric cancer. It had some value for clinical application.展开更多
文摘Abstract Objective： This randomized controlled clinical study was to assess and compare the efficacy and safety of two chemoradiotherapy regimens [cisplatin ＋ 5-fluorouracil ＋ 3 dimensional conformal radiation therapy （3DCRT） and cisplatin ＋ weekly docetaxel ＋ 3DCRT] in patients with locally advanced esophageal squamous cell carcinoma. Methods： A total of seventy-four patients with clinical stages liB to IIIB esophageal squamous cell carcinoma were enrolled. Chemotherapy for PF group comprised 5-fluorouracil at days 1-5 （250 mg/m2/d） and cisplatin （20 mg/m2） at days 1-3 of every 28-day cycle; full treatment course included 2 cycles. Chemotherapy for DP group comprised docetaxel （20 mg/m2） and cisplatin （20 mg/m2） at days 1,8, 15, 22, 29, and 36. Both groups treated with concurrent 60 Gy 3DCRT at 200 cGy/d. Results： Seventy-four patients were enrolled and 71 completed the planned treatment, with a follow-up rate of 95.94%. Short-term curative effect was not statistically significant between the two groups （P = 0.471）. The 2-year survival rates were 65.7% and 61.1%, respectively （P = 0.806）, 5 years survival rates were 34.29% and 27.78%, respectively （P = 0.221）, and there was no significant difference by Fisher test （P = 0.734）. As common side effects, incidence rates of radioactive esophagitis and hematological toxicity were lower in DP group. Conclusion： For locally advanced esophageal cancer patients, current chemoradiotherapy with chemo- therapy regimen of weekly docetaxel plus cisplatin has equal curative effect with 5-fluorouracil plus cisplatin, but well-tolerated by reducing side effects such as radioactive esophagitis and bone marrow suppression.
文摘We report the successful treatment of multiple lung metastases after hepatic resection for hepatocellular carcinoma (HCC) with combined docetaxel, cisplatin (CDDP), and enteric-coated tegafur/uracil (UFT-E). A 68-year-old man was diagnosed with multiple lung metastases of HCC 7 mo after partial hepatectomy for HCC. Oral UFT-E was given daily and docetaxel and CDDP were given intra-arterially (administered just before the bronchial arteries) every 2 wk via a subcutaneous injection port. One month after starting chemotherapy, levels of tumor marker, protein induced by vitamin K absence(PIVKA--), decreased rapidly,and after a further month, chest X-ray and computed tomography revealed the complete disappearance of multiple liver metastases. Two years after the combined chemotherapy, HCC recurred in the liver and was treated but no pulmonary recurrence occurred. In the absence of a standardized highly effective therapy, this combined chemotherapy with docetaxel, CDDP and UFT-E may be an attractive option for multiple lung metastases of HCC.
文摘Objective: The aim of this study was to evaluate the efficacy and toxicity of modified docetaxel, cisplatin and calcium folinate (CF)/5-fluorouracil (mDCF) combination therapy for 27 patients with recurrent or metastatic gastric adeno- carcinoma (R/MGC). Methods: From May 2006 to July 2007, 27 R/MGC patients (18 were male and 9 were female) with a median age of 49 years (range19-66) were consecutively enrolled. The mDCF protocol included 50 mg/m2 docetaxel for 1 day and 25 mg/m2 cisplatin on d2-3, 200 mg/m2 CF on d2-3 and 2000 mg/m2 5-fluorouracil (5-FU) CIV (continous infusion) for 46 h on d2-3, repeated every 2 weeks. Results: Twenty-seven patients were evaluable for efficacy and toxicity. A median of 4.5 cycles was given. One complete and 12 partial responses were observed for an overall intent to treat response rate (RR) 48.1% [95% CI (confidence intervals): 32%-64%]. Median time-to-progression (TTP) was 6.2 months and overall survival (OS) was 11.8 months. Twenty-seven (100%) patients experienced bone marrow suppression, and of them 48.9% were Grade 3-4 (16.3% were Grade 4). Two patients (7.4%) ceased chemotherapy because of bone marrow suppression. WHO Grade 1-4 non-hematological toxicity, such as oral mucositis, nausea/emesia, peripheral neuropathy, liver dysfunction, diarrhea, nephrotoxicity and cardiotoxicity, occurred in 59.2%、51.9%, 48.1%, 44.4%, 25.9%, 18.5% and 11.1% patients, respectively, and most of them were Grade 1-2. No patient died due to chemotherapy toxicity. Conclusion: mDCF regimen is effective in treating R/MGC with a high RR and long TTP/OS in this trial. Despite its severe hematotoxicity, this regimen has some advantages such as no cross-resistance with paclitaxel (paclitaxel-resistant patients RR 2/6). These results suggested that the mDCF regimen worth further investigation in clinical study of R/MGC treatment.
文摘Objective： The aim of this study was to evaluate the clinical efficacy and side effects of docetaxel/cisplatin regiment and gemcitabine/cisplatin regiment in the patients with advanced non-small-cell lung cancer （NSCLC）. Methods： Seventy-six patients with advanced NSCLC who were chemotherapy-naive were enrolled in two groups. In docetaxel group （DP group） the patients received docataxel 75 mg/m^2 and cisplatin 60 mg/m^2 on day 1. In gemcitabine group （GP group） the patients received gemcitabine 1000 mg/m^2 on day 1 and day 8. The dosage of cisplatin was the same as DP group. The two regiments were administrated intravenously every 21 days as a cycle, each patient received 2-4 cycles. All patients were followed up until disease progressed or patients died. Results： The overall response rates were 43.5% in DP group and 45.9% in GP group. The response rate was significantly different between the initial treated group and retreated group in both two groups （53.8% vs 23.0% in DP group and 56% vs 25% in GP group, P 〈 0.05, respectively）. The main side effects were bone marrow suppression and thrombocytopenia. Conclusion： Docetaxel/cisplatin regiment and gemcitabine/cisplatin regiment for the patients with advanced NSCLC were efficient and well-tolerated chemotherapeutic approachs with low toxicity levels. The efficacy and major toxicity in two groups were similar.
文摘Objective： The aim of this study was to investigate the efficacy of weekly docetaxel （TXT）, cisplatin （DDP） combined with continuous infusion of low dose fluorouracil （FU） on advanced gastric carcinoma. Methods： Forty patients with advanced gastric carcinoma were randomly divided into two groups： the research group and the control group with 20 cases in each group. Patients in the research group were given TXT 40 mg/m^2 on dl and d8 plus DDP 30 mg/m^2 on days 1, 3. FU 200 mg/m^2 was infused continually from day 1-14. Patients in control group received ELF regimen therapy. Etoposide （VP- 16） 120 mg/m^2, calcium folinate （CF） 200 mg/m^2, and FU 500 mg/m^2 were given on days 1 and 3. Twenty-eight days were regarded as one cycle. At least two cycles must be completed. The short-term efficacy, adverse reaction, quality of life （QOL）, and overall survival （OS） were recorded. Results： The clinical efficacy could be evaluated in 19 patients of research group and 17 patients in control group. The efficacy of research group was significantly better than that in control group （52.63% vs 17.65%, χ^2 = 4.760, P = 0.041）. However, the difference was not significant in the frequency of adverse reaction, QOL, median survival time, and OS between the two groups （P 〉 0.05）. Conclusion： The short-term efficacy of weekly docetaxel and cisplatin plus low dose FU was better than traditional ELF regimen in the treatment of advanced gastric cancer. It had some value for clinical application.
